Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Calcium gluconate; Magnesium chloride hexahydrate; Boric acid
Bela-Pharm GmbH & Co. KG
QA12AX
Calcium gluconate; Magnesium chloride hexahydrate; Boric acid
240/60/60 milligram(s)/millilitre
Solution for infusion
LR: Licensed Retailer as defined in national legislation
Cattle, Goats, Horses, Pigs, Sheep
Calcium, combinations with vitamin D and/or other drugs
Vitamins and minerals
Authorised
2016-04-22
Health Products Regulatory Authority 30 April 2021 CRN009W0D Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Calcibel 240/60/60 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: ACTIVE SUBSTANCE: Calcium gluconate 240 mg (equivalent to 21.5 mg calcium) Magnesium chloride hexahydrate 60 mg (equivalent to 7.2 mg magnesium) Boric acid 60 mg EXCIPIENT(S): For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for infusion Clear, colourless to slightly yellowish solution 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horse, cattle, sheep, goat, pig. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of acute hypocalcaemia. 4.3 CONTRAINDICATIONS Do not use in cases of: - hypercalcaemia and hypermagnesaemia, - idiopathic hypocalcaemia in foals, - calcinosis in cattle and small ruminants, - septicaemia in the course of acute mastitis in cattle, - chronic renal insufficiency or cases of circulatory or cardiac disorders. Do not use following application of high doses of vitamin D3 preparations. Do not use concomitantly or immediately following application of inorganic phosphorous solutions. Do not use in cases of known hypersensitivity to the active substances. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES In case of acute hypomagnesaemia, the administration of a solution with a higher concentration of magnesium may be necessary. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals During infusion, the product must be administered slowly and at body temperature. Health Products Regulatory Authority 30 April 2021 CRN009W0D Page 2 of 5 During infusion, cardiac rate and rhythm and circulation must be monitored. If any sign of overdose (disturbances of the cardiac rhythm decrease in blood pressure, restlessness) appears, the infusion should be stopped immediately. Special precautions Read the complete document